Changing Services, Changing Oncology Pharmacy COVID-19- An Service Update Survey

In 2020, in response to the COVID pandemic and the impact on cancer care, BOPA produced a statement outlining  recommendations for possible changes to both clinical and operational oncology pharmacy practice.

These changes were accompanied by considerations, potential impacts and wider discussions around management of cancer patients during the COVID pandemic. As  part of BOPAs mission to continue to review and reflect, we are now asking the members to complete a short survey (3-5 min) in order to have a broad understanding  within oncology pharmacy, around which recommendations were implemented, which ones have been continued and challenges of the implementation and ongoing use. This information is essential in the ability of BOPA and the oncology pharmacy community to reflect on lessons learnt during the COVID pandemic. This will help us all plan for the future, both as part of contingency planning for future pandemics and now, when we are facing significant capacity challenges.  We intend on publishing this learning in the new year

Much appreciated

GAP subcommittee

https://www.surveymonkey.co.uk/r/FFGTZMH

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article